Verifying…
Home / Drug A–Z / Valsar-Denk-80

Valsar-Denk-80

NAFDAC Reg. No. C4-1817 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Valsar-Denk-80
NAFDAC number
C4-1817
Active ingredient
Valsartan
Strength
80 mg
Form
Tablet
Pack size
2 x 14's (in Alu-Alu blisters)
Manufacturer
Not listed
Applicant (holder)
Assene-Laborex Limited
Approved
26 Aug 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
25 Aug 2026
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Valsar-Denk-80 is on the NAFDAC register with an active registration (C4-1817). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Valsar-Denk-80 is used for

From the official U.S. FDA label for valsartan, the active ingredient registered with NAFDAC.

Boxed warning: FETAL TOXICITY When pregnancy is detected, discontinue valsartan as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue valsartan as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is used for

Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myocardial infarction , for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults ( 1.3 ) 1.1 Hypertension Valsartan tablets are indicated for the treatment of hypertension, to lowe …

Possible side effects

Hypertension: Most common adverse reactions are headache, dizziness, viral infection, fatigue and abdominal pain ( 6.1 ) Heart Failure: Most common adverse reactions are dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue and hyperkalemia ( 6.1 ) Post-Myocardial Infarction: Most common adverse reactions which caused patients to discontinue therapy are hypotension, cough and increased blood creatinine ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. …

Do not use if

Do not use in patients with known hypersensitivity to any component. Do not coadminister aliskiren with valsartan in patients with diabetes [ see Drug Interactions (7.3) ]. Known hypersensitivity to any component. Do not coadminister aliskiren with valsartan in patients with diabetes ( 4 )

Warnings

Observe for signs and symptoms of hypotension ( 5.2 ) Monitor renal function and potassium in susceptible patients ( 5.3 , 5.4 ) 5.1 Fetal Toxicity Valsartan can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. …

Pregnancy & breastfeeding

IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended ( 8. 2) Pediatrics : Use of valsartan tablets is not recommended in children less than 1 year of age ( 6.1 , 8.4 , 13.2 ) 8.1 Pregnancy Risk Summary Valsartan can cause fetal harm when administered to a pregnant woman. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Valsar-Denk-80

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Valsar-Denk-80

What is in Valsar-Denk-80?

Valsar-Denk-80 contains Valsartan (80 mg), as tablet, according to its NAFDAC registration record.

Is Valsar-Denk-80 registered with NAFDAC?

Yes. Valsar-Denk-80 is listed on the NAFDAC register under registration number C4-1817, and its registration is active as of 5 November 2026.

Has Valsar-Denk-80 been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Valsar-Denk-80 in our automatically synced alert list.

How can I check that my pack of Valsar-Denk-80 is genuine?

Run a free authenticity scan with the NAFDAC number C4-1817, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Valsar-Denk-80 used for?

Valsartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Hypertension, to lower blood pressure in adults and children 1 year and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults ( 1.2 ) Post-myo (Summarised from the official U.S. FDA label for valsartan. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Valsar-Denk-80? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.